KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
HEIDELBERG, Germany, Feb. 29, 2016 -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Florian Fischer, CFO, will present at the Cowen and Company 36th Annual Health Care Conference on Monday, March 7, 2016 at 3:20 p.m. (ET) in Boston.
To access a simultaneous webcast of Dr. Fischers' presentation at the Conference online, log on to http://wsw.com/webcast/cowen30/afmd or go to the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available from Affimed's website for 30 days following the conference. Dr. Fischers' presentation will be available for download in PDF format immediately following the conference presentation in the "Events" section of the Media page of Affimed's website at http://www.affimed.com/events.php.
About Affimed N.V.
Affimed (Nasdaq:AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit www.affimed.com.
CONTACT: IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications
Phone: +49 6221 64793341
E-Mail: [email protected]
